CELLDEX THERAPEUTICS, INC.
CLDX · NASDAQ
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly effect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.
Market Data
Price
$31.67
+0.40 (+1.28%)
Market Cap$2.45B
P/E Ratio—
EPS$—
52W High$35.79
52W Low$19.52
Beta0.87
Data from Finnhub · Updated Jun 15, 2026